Quick Answer
Pelthos Therapeutics Inc. reported Net Income Loss of -$43.32 million for the year ending 2025.
- Pelthos Therapeutics Inc. showed a decrease of -444.6% in Net Income Loss from 2024 to 2025.
- This data is from Pelthos Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$966.6 thousand | Q2 2023: -$953.3 thousand | Q3 2023: -$1.42 million | Q1 2024: -$2.56 million | Q2 2024: -$1.77 million | Q3 2024: -$1.70 million | Q1 2025: -$1.97 million | Q2 2025: -$3.45 million | Q3 2025: -$16.24 million.
- Over the full 4 years of available data (2022 to 2025), Pelthos Therapeutics Inc.'s Net Income Loss has declined by 1,661.9%.
- Historical annual values: Fiscal year 2025: -$43.32 million | Fiscal year 2024: -$7.96 million | Fiscal year 2023: -$7.38 million | Fiscal year 2022: -$2.46 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: